1
Clinical Trials associated with IBRX-042QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose of IBRX-042 in Participants with HPV-Associated Tumors.
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are:
* What is the maximum tolerated dose of IBRX-042?
* How well does the study drug treat cancer?
* What effects the study drug may have on the human body and cancer?
Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.
100 Clinical Results associated with IBRX-042
100 Translational Medicine associated with IBRX-042
100 Patents (Medical) associated with IBRX-042
100 Deals associated with IBRX-042